Docoh
Loading...

ISO IsoPlexis

IsoPlexis is a life science technology company building solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. Our integrated systems, named top innovation or design by the Scientist Magazine, Fierce, BIG Innovation, Red Dot & multiple others, are used globally to advance the field of single-cell biology into new 'omic possibilities, as our customers generate solutions to overcome the challenges of complex diseases and therapeutics. Our products have been adopted by researchers around the world, including the top 15 global pharmaceutical companies by revenue and by nearly half of comprehensive cancer centers in the U.S.

ISO stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

15 Oct 21
31 Dec 21
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
12 Oct 21 Spring Mountain Capital G.P. Common Stock Conversion Acquire C Yes No 0 67,642 0 67,642
12 Oct 21 Spring Mountain Capital G.P. Common Stock Conversion Acquire C Yes No 0 435,136 0 2,270,287
12 Oct 21 Spring Mountain Capital G.P. Common Stock Conversion Acquire C Yes No 0 215,950 0 1,835,151
12 Oct 21 Spring Mountain Capital G.P. Common Stock Conversion Acquire C Yes No 0 415,337 0 1,619,201
12 Oct 21 Spring Mountain Capital G.P. Common Stock Conversion Acquire C Yes No 0 459,781 0 1,203,864
12 Oct 21 Spring Mountain Capital G.P. Common Stock Conversion Acquire C Yes No 0 744,083 0 744,083
12 Oct 21 Spring Mountain Capital G.P. Common Stock Conversion Acquire C Yes No 0 435,136 0 3,726,732
12 Oct 21 Spring Mountain Capital G.P. Common Stock Conversion Acquire C Yes No 0 689,267 0 3,291,596
12 Oct 21 Spring Mountain Capital G.P. Common Stock Conversion Acquire C Yes No 0 739,033 0 2,602,329
12 Oct 21 Spring Mountain Capital G.P. Common Stock Conversion Acquire C Yes No 0 630,209 0 1,863,296

Financial reports

No filings

Proxies

No filings

Patents

GRANT
Utility
Methods for synthesizing nucleotide analogues with disulfide linkers
14 Sep 21
The present invention provides methods, compositions, mixtures and kits utilizing deoxynucleoside triphosphates comprising a 3′-O position capped by a group comprising methylenedisulfide as a cleavable protecting group and a detectable label reversibly connected to the nucleobase of said deoxynucleoside.
GRANT
Utility
Polyphenolic additives in sequencing by synthesis
3 Aug 21
The invention relates to methods, compositions, devices, systems and kits as described including, without limitation, reagents and mixtures for determining the identity of nucleic acids in nucleotide sequences using, for example, sequencing by synthesis methods.
GRANT
Utility
Analysis and screening of cell secretion profiles
20 Jul 21
Embodiments disclose apparatus, methods and software for performing biological screening and analysis implemented using an instrument platform capable of detecting a wide variety of cell-based secretions, expressed proteins, and other cellular components.
APP
Utility
Analysis and Screening of Cell Secretion Profiles
29 Jul 20
Embodiments disclose apparatus, methods and software for performing biological screening and analysis implemented using an instrument platform capable of detecting a wide variety of cell-based secretions, expressed proteins, and other cellular components.
APP
Utility
System and Methods for Multiplexed Analysis of Cellular and Other Immunotherapeutics
27 May 20
Disclosed are methods of identifying a secretome from a subject cell within a heterogeneous cell population when the subject cell contacts a target cell (e.g. a subject immune cell contacts a target cancer cell) or a stimulatory agent and methods of using the identified secretome to identify cells that are safe and efficacious for cellular therapies, including adoptive